Cargando…

Regulation of Ferroptosis in Lung Adenocarcinoma

Lung adenocarcinoma (LUAD) is the most common lung cancer, which accounts for about 35–40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of LUAD patients still remains poor, especially KRAS mutant LUAD. Therefore, it is necessary to further...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiangyun, Li, Xiaohe, Hu, Shuming, Cheng, Jinke, Cai, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572737/
https://www.ncbi.nlm.nih.gov/pubmed/37834062
http://dx.doi.org/10.3390/ijms241914614
_version_ 1785120302617853952
author Wei, Xiangyun
Li, Xiaohe
Hu, Shuming
Cheng, Jinke
Cai, Rong
author_facet Wei, Xiangyun
Li, Xiaohe
Hu, Shuming
Cheng, Jinke
Cai, Rong
author_sort Wei, Xiangyun
collection PubMed
description Lung adenocarcinoma (LUAD) is the most common lung cancer, which accounts for about 35–40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of LUAD patients still remains poor, especially KRAS mutant LUAD. Therefore, it is necessary to further explore novel targets and drugs to improve the prognos is for LUAD. Ferroptosis, an iron-dependent regulated cell death (RCD) caused by lipid peroxidation, has attracted much attention recently as an alternative target for apoptosis in LUAD therapy. Ferroptosis has been found to be closely related to LUAD at every stage, including initiation, proliferation, and progression. In this review, we will provide a comprehensive overview of ferroptosis mechanisms, its regulation in LUAD, and the application of targeting ferroptosis for LUAD therapy.
format Online
Article
Text
id pubmed-10572737
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105727372023-10-14 Regulation of Ferroptosis in Lung Adenocarcinoma Wei, Xiangyun Li, Xiaohe Hu, Shuming Cheng, Jinke Cai, Rong Int J Mol Sci Review Lung adenocarcinoma (LUAD) is the most common lung cancer, which accounts for about 35–40% of all lung cancer patients. Despite therapeutic advancements in recent years, the overall survival time of LUAD patients still remains poor, especially KRAS mutant LUAD. Therefore, it is necessary to further explore novel targets and drugs to improve the prognos is for LUAD. Ferroptosis, an iron-dependent regulated cell death (RCD) caused by lipid peroxidation, has attracted much attention recently as an alternative target for apoptosis in LUAD therapy. Ferroptosis has been found to be closely related to LUAD at every stage, including initiation, proliferation, and progression. In this review, we will provide a comprehensive overview of ferroptosis mechanisms, its regulation in LUAD, and the application of targeting ferroptosis for LUAD therapy. MDPI 2023-09-27 /pmc/articles/PMC10572737/ /pubmed/37834062 http://dx.doi.org/10.3390/ijms241914614 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wei, Xiangyun
Li, Xiaohe
Hu, Shuming
Cheng, Jinke
Cai, Rong
Regulation of Ferroptosis in Lung Adenocarcinoma
title Regulation of Ferroptosis in Lung Adenocarcinoma
title_full Regulation of Ferroptosis in Lung Adenocarcinoma
title_fullStr Regulation of Ferroptosis in Lung Adenocarcinoma
title_full_unstemmed Regulation of Ferroptosis in Lung Adenocarcinoma
title_short Regulation of Ferroptosis in Lung Adenocarcinoma
title_sort regulation of ferroptosis in lung adenocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572737/
https://www.ncbi.nlm.nih.gov/pubmed/37834062
http://dx.doi.org/10.3390/ijms241914614
work_keys_str_mv AT weixiangyun regulationofferroptosisinlungadenocarcinoma
AT lixiaohe regulationofferroptosisinlungadenocarcinoma
AT hushuming regulationofferroptosisinlungadenocarcinoma
AT chengjinke regulationofferroptosisinlungadenocarcinoma
AT cairong regulationofferroptosisinlungadenocarcinoma